search button

The XRCC1 Arg194Trp polymorphism is not a risk factor for glioma: A meta‑analysis involving 1,440 cases and 2,562 controls

  • Authors:
    • Liang Zhang
    • Yan Wang
    • Zhiqun Qiu
    • Jiaohua Luo
    • Ziyuan Zhou
    • Weiqun Shu

  • View Affiliations

  • Published online on: September 18, 2012     https://doi.org/10.3892/etm.2012.716
  • Pages: 1057-1062
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Previous reports have indicated that the X‑ray repair cross‑complementing gene 1 (XRCC1) Arg194Trp polymorphism may be a risk factor for several types of cancer. Published studies on the association of XRCC1 Arg194Trp polymorphisms with glioma risk have yeilded conflicting results. The present study aimed to obtain a more precise estimation of this association. Meta‑analyses assessing the association of the XRCC1 Arg194Trp variation with glioma were conducted and subgroup analyses based on ethnicity and source of controls were also performed. Eligible studies were identified during the period before May 2012. A total of four case‑control studies comprising 1,440 cases and 2,562 controls were finally selected for analysis. The overall data failed to indicate a significant association of the XRCC1 Arg194Trp polymorphism with glioma risk [Trp vs. Arg: odds ratio (OR) = 1.01, 95% confidence interval (95% CI) = 0.77‑1.33; Trp/Trp vs. Arg/Arg: OR = 1.56, 95% CI = 0.96‑2.54; dominant model: OR = 0.98, 95% CI = 0.74‑1.31; recessive model: OR = 1.48, 95% CI = 0.92‑2.38]. Similarly, in the subgroup analysis based on ethnicity and source of controls, no associations were observed. In conclusion, the results of the present study failed to suggest an association between the XRCC1 Arg194Trp polymorphism and glioma risk. Further large and well‑designed studies are required to confirm this conclusion.
View Figures
View References

Related Articles

Journal Cover

December 2012
Volume 4 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.7
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang L, Wang Y, Qiu Z, Luo J, Zhou Z and Shu W: The XRCC1 Arg194Trp polymorphism is not a risk factor for glioma: A meta‑analysis involving 1,440 cases and 2,562 controls. Exp Ther Med 4: 1057-1062, 2012
APA
Zhang, L., Wang, Y., Qiu, Z., Luo, J., Zhou, Z., & Shu, W. (2012). The XRCC1 Arg194Trp polymorphism is not a risk factor for glioma: A meta‑analysis involving 1,440 cases and 2,562 controls. Experimental and Therapeutic Medicine, 4, 1057-1062. https://doi.org/10.3892/etm.2012.716
MLA
Zhang, L., Wang, Y., Qiu, Z., Luo, J., Zhou, Z., Shu, W."The XRCC1 Arg194Trp polymorphism is not a risk factor for glioma: A meta‑analysis involving 1,440 cases and 2,562 controls". Experimental and Therapeutic Medicine 4.6 (2012): 1057-1062.
Chicago
Zhang, L., Wang, Y., Qiu, Z., Luo, J., Zhou, Z., Shu, W."The XRCC1 Arg194Trp polymorphism is not a risk factor for glioma: A meta‑analysis involving 1,440 cases and 2,562 controls". Experimental and Therapeutic Medicine 4, no. 6 (2012): 1057-1062. https://doi.org/10.3892/etm.2012.716